Otsuka's VOYXACT Shows Stronger Kidney Disease Efficacy in Phase 3 Trial
Event summary
- Otsuka presented new Phase 3 VISIONARY trial data at WCN’26 showing VOYXACT achieved 82.5% microscopic hematuria negativity in IgAN patients vs. 52.6% for placebo.
- Median time to hematuria resolution was nine weeks with sibeprenlimab versus 24 weeks with placebo.
- The trial continues to evaluate long-term kidney function preservation over a 24-month period.
- VOYXACT received accelerated approval in 2025 for reducing proteinuria in IgAN patients.
The big picture
Otsuka's positive Phase 3 data for VOYXACT reinforces the potential of APRIL inhibition as a differentiated approach to treating IgA nephropathy, a progressive kidney disease with limited therapeutic options. The results position Otsuka to compete in the growing nephrology market where targeted immunotherapies are gaining traction. Success could expand Otsuka's presence beyond its core neuroscience and oncology franchises.
What we're watching
- Regulatory Pathway
- Whether the accelerated approval will convert to full approval pending long-term kidney function data.
- Competitive Positioning
- How Otsuka positions VOYXACT against emerging IgAN therapies targeting different disease pathways.
- Commercialization Strategy
- The pace at which Otsuka can establish VOYXACT as a standard of care in IgAN treatment.
Our editorial coverage:
Related topics